Actively Recruiting
Randomized, Double-Blind Placebo-Controlled Study of Oral LW402 Tablets for Moderate-to-Severe Atopic Dermatitis Evaluating Efficacy and Safety
Led by Shanghai Longwood Biopharmaceuticals Co., Ltd. · Updated on 2026-08-27
480
Participants Needed
1
Research Sites
39 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the effectiveness and safety of oral LW402 tablets in adults with moderate to severe atopic dermatitis. This Phase 3, randomized, double-blind, placebo-controlled study focuses on patients aged 18 to 75 years who have had atopic dermatitis for at least one year and meet specific diagnostic criteria. The trial is sponsored by Shanghai Longwood Biopharmaceuticals Co., Ltd. Participants are randomly assigned to receive either LW402 tablets at doses of 100 mg or 150 mg twice daily, or placebo tablets, in a parallel study design. The study will assess changes in skin condition and disease severity over 16 weeks of treatment, comparing improvements in the Eczema Area and Severity Index and Investigators Global Assessment scores. During the study, participants will attend regular visits for evaluations including skin assessments and safety monitoring. Researchers will measure the proportion of patients achieving significant improvement in their eczema symptoms at Week 16. The study is planned to run until the end of 2028, with ongoing assessments to ensure safety and efficacy throughout the treatment period.
CONDITIONS
Brief Title
Evaluation of the Efficacy and Safety of Oral LW402 Tablets for the Treatment of Patients With Moderate-to-Severe Atopic Dermatitis
Research Team
B
Barbara Chen
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here